FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS

Greenwich LifeSciences partners with Italy's Gruppo Italiano Mammella (GIM) for Phase III FLAMINGO-01 trial evaluating GLSI-100 immunotherapy to prevent breast cancer recurrences. Nine top GIM institutions join the trial, with Italy being the first country to have all participating sites personally visited and trained by the company.

Precision medicine, originating from the 1990s Human Genome Project, integrates omics data and advanced technologies to personalize healthcare. The field saw significant growth post-2005, driven by NGS advancements, with the U.S. leading in publications and collaborations. Key themes include AI, machine learning, and liquid biopsy, with regional variations influenced by economic and health factors. China focuses on informatics and cancer research, reflecting its disease burden. The study highlights global collaboration trends and the need for regional optimization in precision medicine.

This study assessed MR-guided radiotherapy (MRgRT) efficacy in treating adrenal gland metastasis, using stereotactic body radiation therapy (SBRT) to deliver high doses with minimal exposure to surrounding organs. The study, conducted at LMU University Hospital in Munich and Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, employed secure multiparty computation to ensure data privacy while enabling joint data analysis. The results documented the long-term effectiveness and safety of MRgRT, improving precision and reducing risks to nearby organs.

The Horizon IHI Project, 'Thera4Care - Theranostics Ecosystem for Personalised Care,' aims to develop new cancer treatment tools using imaging techniques and AI, focusing on personalized therapies. Coordinated by Università Cattolica and Fondazione Policlinico Universitario Agostino Gemelli IRCCS, the project involves 29 international partners and is funded by the European Commission with €28 million. The initiative seeks to revolutionize theranostic procedures, particularly for female and gastrointestinal cancers, and establish a European School of Theranostics.